Production (Stage)
Lexicon Pharmaceuticals, Inc.
LXRX
$0.7667
$0.04976.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.30M | -33.77M | -64.81M | -53.43M | -48.40M |
| Total Depreciation and Amortization | 176.00K | 125.00K | 126.00K | 139.00K | 144.00K |
| Total Amortization of Deferred Charges | 401.00K | 401.00K | 402.00K | 525.00K | 517.00K |
| Total Other Non-Cash Items | 177.00K | -19.00K | 974.00K | -25.00K | 4.08M |
| Change in Net Operating Assets | -19.24M | 11.77M | 9.69M | 4.25M | -11.47M |
| Cash from Operations | -43.78M | -21.49M | -53.62M | -48.54M | -55.13M |
| Capital Expenditure | -- | -474.00K | -307.00K | -250.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.58M | 54.17M | 53.78M | -12.07M | -110.22M |
| Cash from Investing | 40.58M | 53.70M | 53.47M | -12.32M | -110.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 1.00K | 88.00K |
| Repurchase of Common Stock | -572.00K | -25.00K | 0.00 | 0.00 | -1.73M |
| Issuance of Preferred Stock | -- | -- | -- | -- | 241.43M |
| Repurchase of Preferred Stock | -- | -78.00K | -10.00K | -15.00K | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.00K | -906.00K | 0.00 | -400.00K |
| Cash from Financing | -572.00K | -104.00K | -916.00K | -14.00K | 239.38M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.77M | 32.11M | -1.07M | -60.88M | 74.03M |